Gain Therapeutics Appoints New CMO, CSO, and Director

TL;DR

Gain Therapeutics beefs up leadership with new CMO, CSO, and board member.

AI Summary

Gain Therapeutics, Inc. announced on June 25, 2024, the appointment of Dr. Marcella R. Ridgeway as Chief Medical Officer and Dr. David M. Recker as Chief Scientific Officer. The company also reported the election of Ms. Jennifer L. Zimmerman to its Board of Directors. These appointments are effective immediately and are part of the company's ongoing efforts to advance its pipeline.

Why It Matters

The appointment of experienced executives in medical and scientific roles, along with a new board member, signals a strategic move by Gain Therapeutics to bolster its leadership and drive forward its drug development programs.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding strategic direction and execution, although the appointments appear to be in line with advancing the company's pipeline.

Key Players & Entities

• Gain Therapeutics, Inc. (company) — Registrant
• Dr. Marcella R. Ridgeway (person) — Appointed Chief Medical Officer
• Dr. David M. Recker (person) — Appointed Chief Scientific Officer
• Ms. Jennifer L. Zimmerman (person) — Elected to Board of Directors
• June 25, 2024 (date) — Effective date of appointments and election

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke

Filing Documents

• tm2418441d1_8k.htm (8-K) — 33KB
• tm2418441d1_ex99-1.htm (EX-99.1) — 14KB
• tm2418441d1_ex99-1img001.jpg (GRAPHIC) — 12KB
• 0001104659-24-076341.txt ( ) — 242KB
• ganx-20240625.xsd (EX-101.SCH) — 3KB
• ganx-20240625_lab.xml (EX-101.LAB) — 33KB
• ganx-20240625_pre.xml (EX-101.PRE) — 22KB
• tm2418441d1_8k_htm.xml (XML) — 4KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departures and Appointments of Executive Officers Matthias Alder On June 25, 2024, Matthias Alder ("Mr. Alder"), Chief Executive Officer of Gain Therapeutics, Inc. (the "Company"), and the Company mutually agreed that his service as Chief Executive Officer of the Company would terminate so that Mr. Alder can pursue other opportunities. Pursuant to Mr. Alder's amended and restated employment letter dated September 20, 2022 (the "Employment Agreement"), Mr. Alder automatically resigned from the Board effective June 25, 2024. In connection with Mr. Alder's departure, the Company entered into a separation and general release agreement with Mr. Alder on June 27, 2024 (the "Separation Agreement"). The Separation Agreement provides, among other things, for Mr. Alder to receive the following: A lump sum payment equal to 12 months of Mr. Alder's current base salary; and COBRA premiums for medical, dental, and vision employee benefit programs, on the same basis as his current coverage election, through the twelve-month anniversary of the effective date of the Separation Agreement. In addition, the Separation Agreement contemplates that any outstanding unvested stock options and restricted stock units held by Mr. Alder shall vest to the extent that such stock options and restricted stock units would have vested had Mr. Alder remained employed with the Company through the one-year anniversary of June 25, 2024. The Separation Agreement further provides for mutual general releases and mutual non-disparagement provisions. Gene Mack On June 27, 2024, Mr. Gene Mack ("Mr. Mack"), the Company's current Chief Financial Officer, was appointed to serve as Interim Chief Executive Officer ("Interim CEO"), effective as June 25, 2024, to fill the vacancy created by Mr. Alder's departure as Chief Executive Officer. Mr. M

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 27, 2024, the Company issued a press release regarding the above. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1 is being furnished to the SEC and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 99.1 Gain Therapeutics, Inc. Press Release dated June 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Date: June 28, 2024 By: /s/ Gene Mack Name: Gene Mack Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR